Advertisement
Journal Home
Search for

Issue

Alert me when new journal issues are available via Request TOC Alert via emailor via Request RSS feed of current issue

previous issue next issue

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4, Pages 413-524 (August 2009)
Search Within This Issue
Incretins
Edited by Michael A. Nauk

display abstract citation download email a colleague
Display:


Preface
Michael A. Nauck
page vii
Full Text | Full-Text PDF (69 KB)


Insulin secretion in healthy subjects and patients with Type 2 diabetes – role of the gastrointestinal tract
Jing Ma, Christopher K. Rayner, Karen L. Jones, Michael Horowitz
pages 413-424
Abstract | Full Text | Full-Text PDF (610 KB)


Immunoassays for the incretin hormones GIP and GLP-1
Carolyn F. Deacon, Jens J. Holst
pages 425-432
Abstract | Full Text | Full-Text PDF (298 KB)


The contribution of incretin hormones to the pathogenesis of type 2 diabetes
Juris J. Meier
pages 433-441
Abstract | Full Text | Full-Text PDF (230 KB)


Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Rolf Mentlein
pages 443-452
Abstract | Full Text | Full-Text PDF (270 KB)


The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Tina Vilsbøll, Jens J. Holst, Filip K. Knop
pages 453-462
Abstract | Full Text | Full-Text PDF (164 KB)


Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
Sten Madsbad
pages 463-477
Abstract | Full Text | Full-Text PDF (191 KB)


Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
Nancy A. Thornberry, Baptist Gallwitz
pages 479-486
Abstract | Full Text | Full-Text PDF (250 KB)


Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
Bo Ahrén
pages 487-498
Abstract | Full Text | Full-Text PDF (263 KB)


Therapeutic potential for GIP receptor agonists and antagonists
Nigel Irwin, Peter R. Flatt
pages 499-512
Abstract | Full Text | Full-Text PDF (356 KB)


Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
M. Nauck, U. Smith
pages 513-523
Abstract | Full Text | Full-Text PDF (293 KB)


Keyword index
page I1
Full-Text PDF (55 KB)

display abstract citation download email a colleague
Display:
Advertisement